Clinical trial
Amifostine in Treating Patients With Myelodysplastic Syndrome
NCT00003048 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003048 |
|---|---|
| Title | Amifostine in Treating Patients With Myelodysplastic Syndrome |
| Official title | Phase II Study of Intravenous Amifostine in Myelodysplastic Syndrome |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Amifostine Trihydrate |
| Enrollment | 12 |
| Start date | Jun 5, 1997 |
| Primary completion | Feb 12, 2001 |
| Completion | Feb 12, 2001 |
| First posted | Sep 6, 2004 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: